Jump to page content

Search results

  • Press release Corona

    What happens in the lungs during SARS-CoV-2 infection

    A Berlin-based research group led by Charité - Universitätsmedizin Berlin has succeeded in simulating SARS-CoV-2 infection in human lungs and has gained important insights into the mechanism of infection. Using living lung samples, they were able to show that the virus is capable of directly infecting the cells of the human alveoli to only a very…

  • Digital Labs

    DHA team around Stefan Verlohren in the German Ärzteblatt

    The suspicion of preeclampsia during pregnancy only ends with serious complications in a few cases. With the help of machine learning, researchers at the Charité - Universitätsmedizin Berlin, funded by the Digital Accelerator, have developed a model that can predict the risk of complications much better than the clinical parameters used to date.

  • Digital Labs

    BIH DHA program featured in Newsweek magazine

    We are happy that our BIH DHA program is featured the international Newsweek magazine about how Berlin leads the way in developing and piloting artificial intelligence solutions in the health sector.

  • News Corona

    Why infection with the Omicron variant may cause less severe COVID-19 disease progression

    Observations from around the globe suggest that the Omicron variant of the SARS-CoV-2 coronavirus is much more infectious than its predecessor, Delta. But on the other hand, Omicron infections seem to cause milder disease: Hospital admissions and the number of deaths have increased only moderately compared to the huge rise in the number of cases.

  • Press release Corona

    The fatal role of T cells in COVID-19

    Scientists from the Berlin Institute of Health at Charité (BIH), together with colleagues from Charité – Universitätsmedizin Berlin and the university hospitals in Bonn and Aachen, have found a type of immune cells that is particularly active in severely ill COVID-19 patients. The CD16 positive T cells have an increased cytotoxic effect, especially…

  • Press release Corona

    Multicenter CATCOVID trial for treating severe COVID-19 progression enrolls first patient

    The clinical phase II trial CATCOVID initiated by the Berlin Institute of Health at Charité (BIH) has cleared the final regulatory hurdles with the receipt of a positive ethics committee vote and with approval from the Federal Institute for Drugs and Medical Devices (BfArM), enrolling its first patient this week at University of Leipzig Medical…

Press contact

Dr. Stefanie Seltmann

Head of Communications, Press Spokesperson

Contact information
Phone:+49 30 450 543 019